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Abstract
Pelvic radiotherapy (RT) has become a vital component of curative treatment for various 
pelvic malignancies. The fixed anatomical position of the rectum in the pelvis and the 
close proximity to the prostate, cervix, and uterus, makes the rectum especially vulner-
able to secondary radiation injury resulting in chronic radiation proctitis (CRP). Clinical 
symptoms associated with CRP are commonly classified by the EORTC/RTOG late radia-
tion morbidity scoring system. Rectal bleeding is the most frequent symptom of CRP 
occurring in 29–89.6% of patients. Endoscopy is essential to determine the extent and 
severity of CRP as well as to exclude other possible causes of inflammation or malignant 
disease. Typical endoscopic findings of rectal mucosal damage in the course of radiation-
induced proctitis include friable mucosa, rectal mucosal hypervascularity, and telangiec-
tases. There is no consensus available for the treatment of CRP, and different modalities 
present a recurrence rate varying from 10 to 30%. CRP can be managed conservatively, 
and also includes ablation (formalin enemas, radiofrequency ablation, YAG laser or argon 
plasma coagulation) as well as some patients require surgery. Although modifications of 
radiation techniques and doses are continually being studied to decrease the incidence of 
CRP, trials investigating preventive methods have been disappointing to date.
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1. Introduction
The discovery of X-rays in 1895 by Wilhelm Röntgen was followed 2 years later by the dis-
covery by Walsh of the damaging effects of X-irradiation on the gastrointestinal tract. In 1912, 
Regaud et al. described delayed changes in the small intestine of a dog following irradia-
tion. Krause and Ziegler believed that harmful effects of X-irradiation on the small intestine 
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were caused by the proliferation of intestinal bacteria [1–4]. In 1917, the first clinical report 
of a patient who developed severe intestinal injury following the use of radiation therapy for 
treatment of malignant disease was published [4]. Then, in 1930, Buie gave the first descrip-
tion of factitial proctitis, which referred to chronic radiation-induced injury to the rectum in a 
group of patients who had undergone pelvic irradiation [3, 5].
Radiotherapy (RT) has now become a common treatment for many cancers involving the 
pelvis, with around 12,000 patients undergoing pelvic radiotherapy in the UK each year, 
over 100,000 American patients annually receiving therapeutic pelvic radiation and up to 
300,000 patients per year worldwide [2, 6, 7]. Pelvic radiotherapy is a vital component of cura-
tive treatment typically used in urological, gynecological and gastrointestinal tract cancers 
(prostate, urinary bladder, cervical, uterine, rectal and anal malignancies). Pelvic radiation is 
administered either as neoadjuvant or adjuvant therapy. After pelvic irradiation, the rectum 
is the commonest site of injury within the gastrointestinal tract. The fixed anatomical position 
of the rectum in the pelvis and the close proximity to the prostate, cervix and uterus make the 
rectum especially vulnerable to secondary radiation injury resulting in proctitis [8–16].
The anterior rectal wall is in close proximity to and partly in continuity with the therapeutic 
target organs (prostate, uterus) [17, 18]. Although the development of late gastrointestinal 
toxicity following pelvic radiotherapy is not entirely dose related, there is a rapid rise in the 
number of rectal complications when the cumulative mean rectal dose and the cumulative 
maximum dose exceed 75 Gy, and there is also evidence that the incidence of severe compli-
cations rises sharply above a total dose of 80 Gy [19–21]. Treatment for prostate carcinoma 
typically receives 75 Gy over 7 to 8 weeks, and cervical carcinoma might receive 45 Gy of 
the typical external beam radiotherapy (EBRT) plus a variable dosing of brachytherapy [22]. 
There is an increasing risk of rectal toxicity ranging from 2% for patients receiving ≤50 Gy to 
15–18% for patients receiving ≥80 Gy [20].
Acute radiation proctitis is encountered by up to 75% of patients receiving conventional pel-
vic radiotherapy and is defined as an inflammatory process involving only the superficial 
mucosa. It occurs within 1–6 weeks of radiation treatment and is generally self-limited with 
symptom resolution often within 3 months after the onset of therapy [2, 4, 6, 8, 12, 23–25]. There 
is some evidence to suggest that moderate or severe chronic radiation proctitis is at least twice 
more likely to occur in those initially experiencing severe acute proctitis [22, 26]. Chronic 
radiation proctitis occurs months to years after treatment with a large majority within 2 years 
post radiotherapy, and this entity is a troublesome complication in those undergoing pelvic 
irradiation for any cause. The incidence of late complications is about 2.5–30%; although with 
improving techniques and newer modalities of radiation therapy and minimizing the dose of 
radiation to the rectum, the incidence is decreasing [2, 4, 6, 8, 12, 15, 20, 22–24, 27–31].
The development of postradiation rectal toxicity is not entirely dose, volume and fraction-
ation schedule related. It also depends on a complex interaction of physical, patient-related 
and genetic factors, but these have been poorly characterized to date [7]. Many patients suffer 
progressive disease that may be life-long. There are a number of predisposing factors that 
may play a role in the increased risk of developing chronic radiation proctitis: age > 60 years, 
low BMI, diabetes, cardiovascular disease, hypertension, peripheral vascular disease, use of 
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anticoagulants, inflammatory bowel disease, hormonal therapy, collagen vascular disease, 
atherosclerosis, preexisting inflammatory bowel disease, smoking, pelvic inflammatory con-
ditions, previous abdominopelvic surgery and possibly secondary anatomical changes with 
intraabdominal adhesions leading to immobility of intestinal loops in the radiation field (e.g., 
hysterectomy), radiation dosages to the lower pelvis >54 Gy, the volume of rectum irradi-
ated, RT technique and dose per fraction, previous concomitant or subsequent chemotherapy, 
ataxia-telangiectasia gene and HIV infection [2, 4, 6, 8, 12, 16, 20, 22, 24, 32, 33].
2. Pathology
Any part of the gastrointestinal tract may be affected by the radiation [4]. Radiotherapy induces 
long-term changes in bowel function as a result of progressive endothelial dysfunction, which 
includes ischemia and subsequent fibrosis. The same processes may cause dysfunction in other 
pelvic organs; therefore, Andreyev et al. defined this disorder as “pelvic radiation disease” 
(PRD). “Proctitis” suggests that there is an ongoing inflammation, whereas there is inflamma-
tion during and immediately after radiotherapy, but, by 3 months or more, inflammation has 
been replaced almost entirely by progressive ischemia and fibrosis. PRD currently affects as 
many each year as develop inflammatory bowel disease (IBD) has a spectrum of symptoms 
identical to IBD and shares some of its pathological features. Unlike IBD, however, we know 
that PRD starts with the initiation of radiotherapy. During therapeutic irradiation of a pelvic 
malignancy, parts of distal small bowel, caecum, transverse and sigmoid colon and rectum are 
often also irradiated. Additionally, the pancreas and proximal small bowel may also receive 
some irradiation if para-aortic nodes are treated. Moreover, in the chronic phase of the disease, 
there is minimal inflammation; “-itis” signifies inflammation, and so describing the situation 
as “-itis” is misleading. So, Andreyev et al. suggest the term “radiation proctopathy” to be bet-
ter. This is not further discussed here because they go beyond the scope of this chapter which 
focuses mainly on chronic radiation proctitis [27, 34–36].
3. Clinical features
Radiation-induced bowel toxicity has been dominated by the application of scoring scales that 
are based on clinical symptoms [7, 27]. Intensity of chronic radiation proctitis is also scored 
with regard to clinical symptoms. Numerous grading systems are used in the literature to 
assess rectal toxicity following radiotherapy. Currently, clinical symptoms associated with 
CRP are most commonly classified by the EORTC/RTOG late radiation morbidity scoring 
system (the European Organization for Research and Treatment of Cancer/Radiation Therapy 
Oncology Group score for late rectal toxicity) (Table 1) [3, 7, 22, 26, 28, 34, 37–40].
Chronic radiation proctitis may be associated with diarrhea, tenesmus, mucus discharge, 
ulcers and abdominal/rectal pain, but bleeding is the most common symptom with poten-
tial iron deficiency anemia that may require hospitalization and even blood transfusions. 
Refractory bleeding is a real challenge to clinicians. The frequency of rectal bleeding after RT 
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is said to occur in 29–89.6% of patients, and it is the second most common reason for referral 
to a gastroenterologists after radiotherapy. Some degree of abdominal or rectal pain affects up 
to 30% of all patients after radiotherapy, and it influences daily living in about 10%. Patients 
may present symptoms of obstructed defecation because of strictures accompanied with con-
stipation, rectal pain, urgency and sometimes fecal incontinence. Fistulas into adjacent organs 
(e.g., vagina) may also occur[4, 6–8, 10, 12, 16, 23, 25, 29, 31, 35, 40, 41].
Because of the nature of radiation injury, the incidence of severe complications (transfusion-
dependent bleeding, fistula formation, rectal stricture and bowel obstruction, perforation, 
secondary malignancy) increases with time. Estimates of the significance of these severe conse-
quences of radiotherapy have varied between 0.5 and 30%, but more reasonable estimates sug-
gest that these occur between 15 and 20% over 20–30 years [4, 7, 12, 42]. Late injury to the rectum 
usually occurs in the first 2–3 years after treatment and the incidence then plateaus [25, 43].
4. Endoscopic findings
Each patient who has undergone radiotherapy for pelvic malignancies and reports symptoms 
suggestive of radiation-induced proctitis should be suspected of this entity, even if irradiation 
was performed many years ago. Endoscopy, in any case, is important to determine the extent 
and severity of chronic radiation proctopathy as well as to exclude other possible causes of 
inflammation or malignant disease [8]. Abnormal endoscopic findings after pelvic radiotherapy 
include congested mucosa, telangiectasia, erythema or pallor, ulceration, stricture, fistula and 
necrosis. Fragile rectal mucosa is prone to bleeding. Telangiectasia of the rectal mucosa which are 
very frequent and a major cause of bleeding may resolve spontaneously after 3 years. However, 
the prevalence of telangiectases in unselected patients is unknown [8, 18, 29, 31, 32, 43].
Endoscopic evaluation of acute radiation proctitis shows edematous, dusky red rectal mucosa, 
whereas endoscopy of chronic radiation proctitis shows mucosal atrophy, ectatic superficial 
capillaries, tortuous blood vessels, telangiectasias, variable stenosis, strictures and fistulas [6]. 
Characteristic endoscopic changes of rectal mucosal damage in the course of radiation proc-
titis are shown in Figure 1.
Proctitis 
grades
Radiation-induced clinical symptoms
0 None
1 Mild diarrhea, mild cramping, bowel movements up to five times daily, slight rectal discharge or 
bleeding, mild anal pain and mild rectal tenesmus
2 Moderate diarrhea and colic, bowel movements more >5 times daily, excessive rectal mucus or 
intermittent rectal bleeding
3 Obstruction or persistent bleeding requiring surgery
4 Necrosis/perforation/fistula
5 Fatal toxicity (sepsis, multiple organ dysfunction syndrome)
Table 1. The EORTC/RTOG scoring system (Radiation Therapy Oncology Group/European Organization for Research 
and Treatment of Cancer score for late radiation proctitis).
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It is also important to highlight that due to the possibility of initiating chronic, poorly heal-
ing wounds and the risk of possible complications of sepsis, fistula formation and also the 
increased risk of bleeding, biopsy of devitalized rectal tissues should be avoided as they 
do not contribute to the diagnosis of chronic radiation proctopathy. Rectal biopsy is only 
justified if any malignancy is suspected or in a case of important therapeutic consequences 
[8, 12, 44].
5. Differential diagnosis
Radiation-induced proctitis should be suspected in any patient after pelvic radiotherapy who 
presents the symptoms of this entity. Acute radiation proctitis may mimic allergic or eosino-
philic colitis, but the history will allow accurate diagnosis. However, endoscopy is essential 
to exclude other causes of acute or chronic proctitis such as infectious colitis, inflammatory 
bowel disease, diversion colitis, ischemic colitis, angiodysplasia, diverticular colitis and con-
comitant other malignancies [6, 8].
6. Treatment: medical and surgical
Radiation-induced proctopathy is unlikely to find one treatment modality that works for all 
patients. Acute radiation-induced proctitis is managed conservatively and includes hydra-
tion, antidiarrheals and steroid or 5-aminosalicylate enemas [12].
There is no consensus available for the treatment of chronic radiation proctopathy, and the dif-
ferent modalities present a recurrence rate varying from 10 to 30%. Chronic radiation-induced 
proctitis can be managed conservatively (anti-inflammatory agents, sucralfate, short-chain 
fatty acids, hyperbaric oxygen therapy, antioxidants) and also includes ablation (formalin 
Figure 1. Typical endoscopic appearance of rectal mucosal damage in the course of radiation proctitis—congested and 
friable mucosa, extensive rectal mucosal hypervascularity, tortuous blood vessels and telangiectases.
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enemas, radiofrequency ablation, YAG laser or argon plasma coagulation) and surgery [12]. 
There was also a case report of successful treatment of a patient with severe refractory hem-
orrhagic radiation proctitis with low dose of oral thalidomide [6, 45]. It is very important 
to realize, when considering invasive treatment that chronic radiation-induced proctitis can 
improve over time without any treatment [8].
6.1. 5-Aminosalicytic acid (5-ASA)
The mechanism of anti-inflammatory action of 5-ASA is the inhibition of prostaglandin synthe-
sis. 5-ASA may also inhibit folate-dependent enzymes and free radical-scavenging activity [12].
6.2. Steroids
Steroids (prednisone, betamethasone, hydrocortisone) have multiple mechanisms of action 
that produce anti-inflammatory effects which extend from stabilization of lysosomes in 
neutrophils to prevent degranulation to upregulation of anti-inflammatory genes via bind-
ing to glucocorticoid receptors [12]. Steroids have been used to treat radiation proctitis 
both alone and in combination with other agents [28]. The addition of metronidazole to oral 
mesalazine and betamethasone enemas was associated with a reduction in rectal bleeding, 
diarrhea and ulcers [8].
6.3. Sucralfate and pentosan polysulfate (PPS)
Sucralfate (2–3 g of sucralfate in a 15–20 ml suspension, oral sucralfate, paste) adheres to 
mucosal cells and stimulates epithelial healing and the formation of protective epithelial bar-
rier while PPS (a synthetic derivative of a glycosaminoglycan) is thought to reduce epithelial 
permeability and prevent adherence similar to sucralfate. Moreover, sucralfate has been found 
to induce a better clinical response than anti-inflammatories in patients with CRP. Based on 
a Cochrane review, sucralfate enemas were more effective than corticosteroid or mesalazine 
enemas [8, 12, 22, 28, 35, 39]. A novel method of rectal administration of sucralfate via a low-
volume sucralfate paste (two sucralfate 1 g tablets mixed with 4.5 ml of water) was reported 
by McElvanna et al. Clinical improvement was reported in 73% of patients, and 32% had 
resolution of all symptoms [39].
PPS, a fibrinolytic, anti-inflammatory and mucoprotective agent, resolved symptoms in nine 
of thirteen patients with established chronic radiation proctitis [20].
6.4. Short-chain fatty acids (SCFAs)
Short-chain fatty acids are the main energy source for colonocytes and stimulate colonic 
mucosal proliferation. The most important product of SCFA is butyric acid. They also exert 
a vasodilatatory effect on the arteriole walls to improve blood flow. SCFAs were found to 
accelerate the healing process, with a significant early reduction in bleeding episodes and 
endoscopic scores. One of two small randomized, placebo-controlled trials noted more rapid 
improvement in symptoms and endoscopic findings in a group of patients using a butyrate-
containing SCFAs solution over a 5-week period compared with placebo controls [12, 22, 28].
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6.5. Formalin
Formalin application has been demonstrated to be generally effective and safe in hemorrhagic 
proctitis and, however, may cause complications such as chronic anorectal pain, fever, fecal 
incontinence, rectosigmoid necrosis with or without perforation, enteric fistula formation, 
anal and rectal strictures as well as pelvic sepsis. Topical formalin instillation (4% solution, 
formalin-soaked pads with up to 10% solution) may be repeated in case of recurrent bleeding 
and combined with other methods [9, 12, 20, 31, 35, 40, 41, 46, 47]. Formalin enemas probably 
reduce mucosal blood flow, sclerose and seal fragile telangiectasias through chemical cauter-
ization to prevent further bleeding with reported success rate of 48–100%. Direct contact with 
formalin for 2–3 minutes (via formalin solution installation through endoscope or Foley cath-
eter or soaked gauze) causes chemical cauterization of neovasculature [9, 12, 35, 40, 41, 47].
6.6. Antioxidants
As oxidative stress is thought to be an important factor in the development of chronic radia-
tion proctitis, antioxidants have been used in an attempt to limit tissue damage. The use of 
vitamins E (400 IU three times daily), C (500 mg three times daily) and A (10,000 IU twice daily 
for 90 days) significantly reduced proctitis symptoms (diarrhea, bleeding, urgency) [8, 12, 48].
6.7. Endoscopic treatment
A variety of endoscopic coagulation devices (e.g., Nd:YAG laser, argon plasma coagulation, 
bipolar electrocoagulation, and heater probe) deliver thermal coagulation to the focal bleed-
ing telangiectasia and should be reserved for patients suffering from significant hemorrhagic 
proctitis. There have been also reports on endoscopic balloon dilatation and stenting for 
 radiation-induced rectal strictures [12, 28].
Argon plasma coagulation (APC)—monopolar diathermy is used to ionize the argon gas which 
coagulates the telangiectatic vessels in a noncontact fashion (0.8–3.0 mm from the target). 
Many gastroenterologists consider APC as the treatment of choice for CRP. A complete resolu-
tion of bleeding is obtained in 70–80% of patients, but an average of three treatment sessions 
is required. On the other hand, we have to realize severe complications that may happen after 
this procedure which is performed in chronically ischemic tissues (deep ulceration, fistulation, 
rectal stenosis, rebound bleeding, long-term pain, perforation, rectovaginal fistula and even 
bowel explosions in inadequately prepared bowels). The development of rectal ulcers after 
APC is thought to be a consequence of thermal injury. On the basis of anecdotal evidence, APC 
is commonly ineffective in patients with very heavy bleeding [8, 12, 15, 20, 25, 31, 35, 47, 49].
YAG laser coagulation has a similar benefit as APC with a limited depth of penetration and the 
possibility for precise application. The major risk for laser coagulation is transmural necrosis, 
with perforation or stricture formation. Nevertheless, the laser is expensive and not widely 
available [8, 12, 20, 31].
Trans-anal rectoscopic ball diathermy (TARD)—monopolar diathermy coagulation is used to coag-
ulate radiation-induced hemorrhagic telangiectasia (RIHT). Treatment involves applications of 
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monopolar diathermy to the rectal mucosa over the affected areas, targeting the central “feeding 
vessel” of the telangiectatic spots. TARD is a safe and effective modality with 85% of patients 
reporting immediate symptomatic control with no significant morbidity [46].
Endoscopic cryoablation (cryospray ablation therapy) involves noncontact application of liquid 
nitrogen or carbon dioxide gas to the tissue and offers superficial ablation of mucosa in 
patients with CRP. Cryotherapy has been suggested as a safe and effective method for bleed-
ing in CRP. Hou et al. reported a series of ten patients with hemorrhagic radiation proctitis 
treated with endoscopic cryoablation. Overall subjective clinical scores improved as deter-
mined by the Radiation Proctitis Severity Assessment Scale from 27.7 to 13.6 (p = 0.003), and 
symptom improvement correlated with endoscopic improvement. Cryotherapy is novel and 
up to date, and there is very limited data [15, 24, 47].
6.8. Hyperbaric oxygen therapy (HBOT)
HBOT involves patients breathing pure oxygen in a pressurized room or tube. Under these 
conditions, the lungs can gather more oxygen than at normal air pressure. Higher oxygen-
ated blood may inhibit bacterial growth and stimulate the release of growth factors and stem 
cells; thus, it affects and promotes wound healing. Increased oxygen pressure to telangiec-
tatic vessels reverses the ischemic component of chronic radiation proctopathy and promotes 
angiogenesis with healing of rectal mucosa. Two randomized controlled trials (RCTs) and 
one nonrandomized comparative study examined HBOT for treatment of radiation proctitis. 
First, RTC showed a significantly greater proportion of HBOT patients demonstrating at least 
moderate healing of proctitis in comparison with sham treatment group immediately after 
completion of treatment (87.5 vs. 62.5%, p = 0.0009). The second RTC reported that treatment 
with HBOT significantly decreased the prevalence of radiation proctitis compared to symp-
tomatic treatment alone at 6-month follow-up (76.9 vs. 42.9%, p = 0.026). The nonrandomized 
comparative study found that HBOT patients required statistically more blood transfusions 
than APC (argon plasma coagulation) patients at 1-month (p = 0.03) and 2-month follow-up 
(p = 0.04). This difference was nonsignificant after 3 months. Side effects after HBOT may 
include barotrauma (ear pain), myopia and confinement anxiety [8, 24, 31, 47, 50].
As late radiation injury is characterized by abnormal angiogenesis, the future will show 
whether it will be possible to develop drugs to treat radiation proctitis with angiogenic fac-
tors as their target. Inhibitors of angiogenic factors such as angiogenin and fibroblast growth 
factor 1 (FGF1) might be also effective for treating CRP [51].
6.9. Surgery
Surgery is a feasible curative option for severe cases refractory to medical treatment; how-
ever, there is no universally agreed surgical first-line approach in the literature, indicating 
which patients should undergo surgery nor which surgical procedure is optimal. On the other 
hand, surgery in previously irradiated patients is often extremely difficult because of fibrosis 
within the abdomen and carries significantly higher risks of complications and mortality than 
surgery in nonirradiated patients. Thus, surgery is reserved solely as a last resort; neverthe-
less, the challenge for clinicians is to develop an evidence-based consensus to decide when 
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the benefits of surgery outweigh the risks in the group of patients refractory to conservative 
treatment [7, 8, 14, 23, 28, 41]. Reported data on the increasing risk over time of complications 
requiring operative intervention show that 4–10% of patients are affected over 5–10 years and 
up to 20% over 20 years [27]. Generally, approximately 2.6–10% and even up to one-third of 
the patients will undergo surgery due to complications of radiation proctitis. The preferred 
surgical approach is not universally agreed. Surgery for CRP mainly involves either diverting 
loop colostomy or resection without primary anastomosis. The issue with diversion alone for 
CRP is that it does not remove the damaged tissue, and leaving it in situ leaves the patient 
at risk of further bleeding, perforation, obstruction and abscess formation. Therefore, some 
authors advocate that if patients are fit enough, resection should be the first-line therapy, and 
defunctioning stoma reserved for patients who are poor surgical candidates for resection. 
Another option is resection with loop ileostomy. Diversion of stool or the urinary stream with 
an ostomy or a suprapubic catheter should be considered in almost all cases where repair is 
attempted. In cases of complicated fistulous disease, particularly when accompanied by sig-
nificant pain and incontinence, a proctectomy or pelvic exenteration with or without recon-
struction is recommended. In cases of severe and intractable bleeding, proctectomy may be 
the only option [8, 12, 20, 23, 41]. The most common indications for surgical management in 
patients with chronic radiation proctitis are shown in Table 2 [12, 20, 23, 28].
When surgical treatment is needed, most studies demonstrate poor outcomes with compli-
cation rates of 15–80% (sepsis, wound dehiscence, bowel obstruction, de novo rectal fistula) 
and a mortality of 3–9% and even up to 25% [8, 12, 20]. In contrary to diversion alone, major 
resectional surgery carries higher morbidity and mortality risks. Mortality and morbidity 
vary from 0 to 44% and from 0 to 11% for diversion only vs. 0–100% and 0–14% in cases of 
resectional surgery [23].
7. Prevention
Although modifications of radiation techniques and doses are continually being studied to 
decrease the incidence of radiation-induced proctitis, trials investigating preventive meth-
ods have been disappointing to date. The role of pharmacological and nutritional therapy 
in reducing radiation-induced gut disease has been evaluated in a variety of experimental 
settings, including animal models (e.g., pravastatin, teduglutide). Agents that reverse fibrosis 
Indications for surgery
• Failure of conservative treatment (intractable bleeding)
• Strictures and rectal obstruction
• Rectal or rectosigmoid perforation
• Fistulas (e.g., recto-vaginal, rectovesical, recto-urethral)
• Uncontrollable rectal pain
Table 2. Indications for surgery in patients with chronic radiation proctitis.
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might be useful but need to be taken for many months to produce benefit. Many treatments 
have potential antifibrotic activity (liposomal copper-zinc superoxide dismutase, pentoxifyl-
line with or without high-dose vitamin E and hyperbaric oxygen). Balsalazide used 5 days 
before and up to 2 weeks after pelvic radiotherapy proved an improvement in toxicity grades, 
particularly pertaining to proctitis. Diets enriched with glutamine, arginine and vitamin E 
have been shown to have a protective effect on the intestinal mucosa of rats treated with 
radiotherapy. However, there are no trials assessing the role of dietary supplements in attenu-
ating the development of chronic radiation enteritis in humans [2, 7, 12, 35, 48]. Preventative 
measures (e.g., the use of rectal misoprostol, oral or rectal sucralfate) have not made a signifi-
cant contribution to decrease the incidence of radiation proctitis. However, data available in 
the literature are ambiguous. Khan et al. found that misoprostol rectal suppositories given 
prior to each radiotherapy session reduced acute and chronic proctitis syndrome [12, 22].
Optimizing the radiotherapy planning by using planning constraints reduces the irradiated 
rectal volume and, thus, decreases the risk of rectal toxicity. Appropriate packing to push 
the rectum and bladder away from the radioactive source helps in reducing the incidence of 
radiation proctitis. There is also evidence in favor of genetic variants in the development of 
radiation toxicity. Therefore, there is a role for further studies to identify high-risk patients 
based on genetic biomarkers [4, 8].
Author details
Radzislaw Trzcinski*, Michal Mik, Lukasz Dziki and Adam Dziki
*Address all correspondence to: trzcinskir@wp.pl
Department of General and Colorectal Surgery, Medical University of Lodz, Lodz, Poland
References
[1] Somozy Z, Horváth G, Telbisz Á, et al. Morphological aspects of ionizing radiation res-
ponse of small intestine. Micron. 2002;33:167-178
[2] Theis VS, Sripadam R, Ramani V, et al. Chronic radiation proctitis. Clinical Oncology. 
2010;22:70-83
[3] Bielecki K. Chronic radiation proctitis (CRP). Nowa Medycyna. 2014;3:99-106
[4] Sharma B, Pandey D, Chauhan V, et al. Radiation proctitis. JIACM. 2005;6(2):146-151
[5] Buie LA, Malmgren GE. Factitial proctitis. Transactions American Proctologic Society. 
1930;29:80-84
[6] Weisenberg E. Anus and Perianal Area – Radiation Proctitis. Last major update October 
2014. Available from: http://www.pathologyoutlines.com/topic/anusradiationproctitis.html
Proctological Diseases in Surgical Practice114
[7] Andreyev HJN. Gastrointestinal problems after pelvic radiotherapy: The past, the pres-
ent and the future. Clinical Oncology. 2007;19:790-799
[8] Vanneste BGL, De Voorde LV, de Ridder RJ, et al. Chronic radiation proctitis: Tricks to 
prevent and treat. International Journal of Colorectal Disease. 2015;30:1293-1303
[9] Dziki Ł, Kujawski R, Mik M, et al. Formalin therapy for hemorrhagic radiation proctitis. 
Pharmacological Reports. 2015;67:896-900
[10] Williams HRT, Vlavianos P, Blake P, et al. The significance of rectal bleeding after pelvic 
radiotherapy. Alimentary Pharmacology & Therapeutics. 2005;21:1085-1090
[11] Denton AS, Andreyev HJN, Forbes A, Maher EJ. Systematic review for non-surgical 
intervention for the management of late radiation proctitis. British Journal of Cancer. 
2002;87(2):134-143
[12] Do NL, Nagle D, Poylin VY. Radiation proctitis: Current strategies in  management. 
Gastroenterology Research and Practice 2011;2011:9. Article ID 917941. DOI: 10.1155/ 
2011/917941
[13] Varma JS, Smith AN, Busuttil A. Function of the anal sphincters after chronic radiation 
injury. Gut. 1986;27:528-533
[14] Counter SF, Froese DP, Hart MJ. Prospective evaluation of formalin therapy for radia-
tion proctitis. American Journal of Surgery. 1999;177:396-398
[15] Tang SJ, Bhaijee F. Chronic radiation proctopathy and colopathy. Video Journal and 
Encyclopedia of GI Endoscopy. 2013;1:307-308
[16] Babb RR. Radiation proctitis: A review. The American Journal of Gastroenterology. 1996; 
91:1309-1311
[17] Hovdenak N, Fajardo LF, Hauer-Jensen M. Acute radiation proctitis: A sequential 
clinicopathologic study during pelvic radiotherapy. International Journal of Radiation 
Oncology, Biology, Physics. 2000;48:1111-1117
[18] Krol R, Smeenk RJ, van Lin ENJT, et al. Systematic review: Anal and rectal changes 
after radiotherapy for prostate cancer. International Journal of Colorectal Disease. 2014; 
29:273-283
[19] Gami B, Harringtom K, Blake P, et al. How patients manage gastrointestinal symptoms 
after pelvic radiotherapy. Alimentary Pharmacology & Therapeutics. 2003;18:987-994
[20] O’Brien PC. Radiation injury of the rectum. Radiotherapy and Oncology. 2001;60:1-14
[21] Ogino I, Kitamura T, Okamoto N, et al. Late rectal complications following high dose rate 
intracavitary brachytherapy in cancer of the cervix. International Journal of Radiation 
Oncology, Biology, Physics. 1995;31:725-734
[22] Kennedy GD, Heise CP. Radiation colitis and proctitis. Clinics in Colon and Rectal 
Surgery. 2007;20:64-72
Radiation Proctitis
http://dx.doi.org/10.5772/intechopen.76200
115
[23] McCrone LF, Neary PM, Larkin J, et al. The surgical management of radiation proctopa-
thy. International Journal of Colorectal Disease. 2017;32:1099-1108
[24] Garg AK, Mai WY, McGary JE, et al. Radiation proctopathy in the treatment of prostate 
cancer. International Journal of Radiation Oncology, Biology, Physics. 2006;66:1294-1305
[25] Chruscielewska-Kiliszek MR, Rupinski M, Kraszewska E, et al. The protective role 
of antiplatelet treatment against ulcer formation due to argon plasma coagulation in 
patients treated for chronic radiation proctitis. Colorectal Disease. 2014;16:293-297
[26] Denham JW, O’Brien PC, Dunstan RH, et al. Is there more than one late radiation proc-
titis syndrome? Radiotherapy and Oncology. 1999;51:43-53
[27] Andreyev HJN, Wotherspoon A, Denham JW, et al. “Pelvic radiation disease”: New 
understanding and new solutions for a new disease in the era of cancer survivorship. 
Scandinavian Journal of Gastroenterology. 2011;46:389-397
[28] Hayne D, Vaizey CJ, Boulos PB. Anorectal injury following pelvic radiotherapy. The 
British Journal of Surgery. 2001;88:1037-1048
[29] Nasierowska-Guttmejer A. Changes in the gastrointestinal mucosa after radio- and che-
motherapy of the neoplasms. Oncology Review. 2012;2:39-44
[30] Takemoto S, Shibamoto Y, Ayakawa S, et al. Treatment and prognosis of patients with 
late rectal bleeding after intensity-modulated radiation therapy for prostate cancer. 
Radiation Oncology. 2012;7:87
[31] Leiper K, Morris AI. Treatment of radiation proctitis. Clinical Oncology. 2007;19:724-729
[32] Kim TG, Huh SJ, Park W. Endoscopic findings of rectal mucosal damage after pelvic 
radiotherapy for cervical carcinoma: Correlation of rectal mucosal damage with radia-
tion dose and clinical symptoms. Journal of Radiation Oncology. 2013;31:81-87
[33] Shadad AK, Sullivan FJ, Martin JD, et al. Gastrointestinal radiation injury: Symptoms, 
risk factors and mechanisms. World Journal of Gastroenterology. 2013;19(2):185-198
[34] Andreyev HJN, Benton BE, Lalji A, et al. Algorithm-based management of patients with 
gastrointestinal symptoms in patients after pelvic radiation treatment (ORBIT): A ran-
domised controlled trial. Lancet. 2013;382:2084-2092
[35] Andreyev J. Gastrointestinal symptoms after pelvic radiotherapy: A new understanding 
to improve management of symptomatic patients. The Lancet Oncology. 2007;8:1007-1017
[36] Andreyev HJN. Pelvic radiation disease. Colorectal Disease. 2015;17:2-6
[37] Goldner G, Tomicek B, Becker G, et al. Proctitis after external-beam radiotherapy for 
prostate cancer classified by Vienna rectoscopy score and correlated with EORTC/RTOG 
score for late rectal toxicity: Results of a prospective multicenter study of 166 patients. 
International Journal of Radiation Oncology, Biology, Physics. 2007;67:78-83
[38] Wachter S, Gerstner N, Goldner G, et al. Endoscopic scoring of late rectal mucosal dam-
age after conformal radiotherapy for prostatic carcinoma. Radiotherapy and Oncology. 
2000;54:11-19
Proctological Diseases in Surgical Practice116
[39] McElvanna K, Wilson A, Irwin T. Sucralfate paste enema: A new method of topical treat-
ment for haemorrhagic radiation proctitis. Colorectal Disease. 2014;16:281-284
[40] Ma TH, Yuan ZH, Zhong QH, et al. Formalin irrigation for hemorrhagic chronic radia-
tion proctitis. World Journal of Gastroenterology. 2015;21(12):3593-3598
[41] Wong MTC, Lim JF, Ho KS, et al. Radiation proctitis: A decade’s experience. Singapore 
Medical Journal. 2010;51:315-319
[42] Eifel PJ, Levenback C, Wharton JT, et al. Time course and incidence of late complications 
in patients treated with radiation therapy for FIGO Stage IB carcinoma of the uterine 
cervix. International Journal of Radiation Oncology, Biology, Physics. 1995;32:1289-1300
[43] O’Brien PC, Hamilton C, Denham JW. Spontaneous improvement in late rectal muco-
sal changes after radiotherapy for prostate cancer. International Journal of Radiation 
Oncology, Biology, Physics. 2004;58:75-80
[44] Gilinsky NH, Burns DG, Barbezat GO, et al. The natural history of radiation-induced 
proctosigmoiditis: An analysis of 88 patients. The Quarterly Journal of Medicine, New 
Series LII. 1983;205(Winter):40-53
[45] Craanen ME, van Triest B, Verheijen RHM, et al. Thalidomide in refractory haemor-
rhagic radiation induced proctitis. Gut. 2006;55:1371-1372
[46] Hopkins JC, Wood JJ, Gilbert H, et al. Trans-anal rectoscopic ball diathermy (TARD) 
for radiotherapy-induced haemorrhagic telangiectasia: A safe and effective treatment. 
Colorectal Disease. 2013;15:566-568
[47] Hou JK, Abudayyeh A, Shaib Y. Treatment of chronic radiation proctitis with cryoabla-
tion. Gastrointestinal Endoscopy. 2011;73:383-389
[48] Hauer-Jensen M, Wang J, Denham JW. Bowel injury: Current and evolving management 
strategies. Seminars in Radiation Oncology. 2003;13:357-371
[49] Sudha AP, Kadambari D. Efficacy and safety of argon plasma coagulation in the man-
agement of extensive chronic radiation proctitis after pelvic radiotherapy for cervical 
carcinoma. International Journal of Colorectal Disease. 2017;32:1285-1288
[50] Hoggan BL, Cameron AL. Systematic review of hyperbaric oxygen therapy for the treat-
ment of non-neurological soft tissue radiation-related injuries. Support Care Cancer. 
2014;22:1715-1726
[51] Takeuchi H, Kimura T, Okamoto K, et al. A mechanism for abnormal angiogenesis in 
human radiation proctitis: analysis of expression profile for angiogenic factors. Journal 
of Gastroenterology. 2012;47:56-64
Radiation Proctitis
http://dx.doi.org/10.5772/intechopen.76200
117

